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Abstract
Objectives: To address whether the use of methotrexate (MTX) and biological disease-modifying anti-rheumatic
drugs (bDMARDs) impacts bone structure and biomechanical properties in patients with psoriatic arthritis (PsA).
Methods: This is a cross-sectional study in PsA patients receiving no DMARDs, MTX, or bDMARDs. Volumetric bone
mineral densities (vBMDs), microstructural parameters, and biomechanical properties (stiffness/failure load) were
determined by high-resolution peripheral quantitative CT and micro-finite element analysis in the respective groups.
Bone parameters were compared between PsA patients with no DMARDs and those receiving any DMARDs, MTX,
or bDMARDs, respectively.
Results: One hundred sixty-five PsA patients were analyzed, 79 received no DMARDs, 86 received DMARDs, of
them 52 bDMARDs (TNF, IL-17- or IL-12/23 inhibitors) and 34 MTX. Groups were balanced for age, sex,
comorbidities, functional index, and bone-active therapy, while disease duration was longest in the bDMARD group
(7.8 ± 7.4 years), followed by the MTX group (4.6 ± 7.4) and the no-DMARD group (2.9 ± 5.2). No difference in bone
parameters was found between the no-DMARD group and the MTX group. In contrast, the bDMARD group
revealed significantly higher total (p = 0.001) and trabecular vBMD (p = 0.005) as well as failure load (p = 0.012) and
stiffness (p = 0.012). In regression models, age and bDMARDs influenced total vBMD, while age, sex, and bDMARDs
influenced failure load and stiffness.
Conclusion: Despite longer disease duration, bDMARD-treated PsA patients benefit from higher bone mass and
better bone strength than PsA patients receiving MTX or no DMARDs. These data support the concept of better
control of PsA-related bone disease by bDMARDs.
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Introduction
Psoriatic arthritis (PsA) is a chronic inflammatory joint
disease associated with psoriasis characterized by periph-
eral arthritis and enthesitis leading to structural damage
[1–3]. Bone erosions and enthesiophytes are hallmarks of
local structural damage in PsA. More recently, the impact
of PsA on systemic bone is increasingly appreciated.
Hence, systemic bone loss has been documented to occur
in PsA [4, 5] and increased prevalence of fractures in PsA
patients is reported [6].
In contrast to RA, little is known about the effect of
disease-modifying anti-rheumatic drugs (DMARDs) on
bone structure in PsA. In rheumatoid arthritis (RA), bio-
logical DMARDs (bDMARDs) have shown to inhibit bone
loss and thus may prevent pathological fractures [7–9]. To
date, no such studies have been done in PsA; however, it
can be assumed that effective control of inflammation may
also impact secondary bone loss and bone biomechanics in
PsA patients. In support of this notion, bDMARD treat-
ment in PsA patients retards the progression of
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periarticular bone erosions [10–12] and periarticular bone
loss [13–15]. Whether systemic bone mass and bone bio-
mechanical properties are influenced by DMARD treat-
ment is unclear to date. Furthermore, methotrexate
treatment may not necessarily share potential beneficial ef-
fects of bDMARDs on bone in PsA patients.
While dual-energy X-ray absorptiometry (DXA) or
digital X-ray radiogrammetry (DXR) can quantify bone
loss, they do not allow separate assessment of changes in
the cortical and trabecular bone compartment or the
biomechanical properties of bone. High-resolution per-
ipheral quantitative CT (HR-pQCT) enables the analysis
of bone mass and microstructure and via integration of
micro-finite element analysis (μFEA) the assessment of
bone strength [16]. An HR-pQCT study in RA patients
has already shown that the biomechanical properties of
the bone are reduced in RA patients [17].
To investigate whether DMARD treatment influences
systemic bone structure and function in PsA patients,
we investigated bone density, bone microstructure, and
biomechanical properties in patients receiving either no
DMARDs, methotrexate (MTX) treatment, or biologic
DMARDs (bDMARDs) by HR-pQCT. In this cross-
sectional study, we were specifically interested, whether
PsA patients treated with either MTX or bDMARDs
show a better bone structure and function than PsA pa-
tients receiving no DMARDs.
Methods
Psoriatic arthritis patients
PsA patients were part of the Erlangen Imaging Cohort
(ERIC), which prospectively assesses bone composition in
patients with inflammatory arthritis [18]. All participants
were consecutively recruited during routine diagnostic as-
sessments at the Department of Internal Medicine 3 of the
University of Erlangen-Nuremberg. Patients were examined
by experienced rheumatologists (AK, JR, AJH) and had to
fulfill the Classification criteria for Psoriatic Arthritis (CAS-
PAR) [19]. Age, sex, and smoking habits were recorded.
With respect to psoriatic disease, duration of PsA, duration
of psoriasis, minimal disease activity (MDA) state, disease
activity in psoriatic arthritis (DAPSA), Psoriasis Area and
Severity Index (PASI), dermatology life quality index
(DLQI), health assessment questionnaire (HAQ), nail and/
or scalp involvement, anti-rheumatic and bone-active medi-
cation, and laboratory parameters (rheumatoid factor, anti-
citrullinated protein antibodies) were collected. Patients
were categorized into three different treatment groups: (A)
methotrexate monotherapy (over at least 6months), (B)
bDMARDs (without MTX) including TNF inhibitors, secu-
kinumab and ustekinumab (over at least 6months), and (C)
a control group of PsA patients receiving no DMARDs over
the last 6months. The no-DMARD group included pa-
tients that for different reasons were not on DMARDs
including (i) treatment-naïve patients at their first visit; (ii)
treatment-naïve patients who had mild disease that was not
considered to require immediate DMARD treatment; (iii)
DMARD pre-exposed patients that had stopped treatment
for compliance, intolerance, or lack of efficacy; and (iv) pa-
tients that were in drug-free remission. The study was con-
ducted on approval of the local ethics committee of the
University Clinic of Erlangen. Each individual provided in-
formed consent.
HR-pQCT measurement
HR-pQCT was performed at the distal radius (dominant
hand) by an XtremeCT scanner (Scanco Medical, Brütti-
sellen, Switzerland). The following bone parameters were
assessed: volumetric bone mineral density (vBMD) of
the total, trabecular, meta-trabecular, inner trabecular,
and cortical bone (all: mg HA/cm3) and ratio of meta-
to-inner density (%) and cross-sectional bone area
(mm2). Bone microstructure was assessed by determin-
ing trabecular bone volume fraction (%), trabecular
number (1/mm), thickness (mm), separation (mm), net-
work inhomogeneity (SD of 1/trabecular number (mm)),
and cortical thickness (mm) [20–22].
Micro-finite element analysis
For micro-finite element analysis (μFEA), finite element
analysis software (FAIM, version 8.0, Numerics88 solu-
tion, Calgary, Canada) was used. In order to generate
micro-finite element models, the segmented trabecular
network and cortex of the HR-pQCT images were used
[23]. Mesh size of the resulting models ranged from 1.5
to 3.5 million equally sized brick elements. Single linear
isotropic tissue modeling was applied by assigning a tis-
sue modulus of 6829MPa and a Poisson’s ratio of 0.3
homogeneously to each element [16]. A linear uniaxial
compression test was simulated. Nodes on the proximal
bone surface were fixed in z direction but unconstrained
in x and y directions. Nodes on the distal bone surface
were also free in the x and y directions but exposed to a
displacement equivalent to 1% strain along the z axis
[16]. Axial bone stiffness (kN/mm) as reaction force
(RFz) divided by average displacement of the distal sur-
face (Uz) and bone strength as estimated failure load (N)
based on the Pistoia criterion was calculated [24].
Statistical analysis
Statistical analyses compared PsA patients treated by
bDMARDs or methotrexate to patients receiving no
DMARD with respect to vBMD, bone microstructure,
and biomechanical properties. Categorical variables are
presented as numbers and percentages, and continuous
variables as mean ± SD. Frequency distributions of cat-
egorical variables were compared using χ2 tests. Clinical,
bone structural, and μFEA parameters were compared
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by using Kruskal-Wallis test (KW) with subsequent pair-
wise Mann-Whitney U tests, if KW test was significant.
In order to account for multiple testing, we applied
Bonferroni-Holm adjustment for pairwise comparisons.
Critical p values for adjusted levels of significance are
shown in the corresponding tables. Finally, we fitted lin-
ear regression models to contrast the differences in HR-
pQCT and μFEA measurements with methotrexate and
bDMARD use in comparison to no DMARDs. Models
were adjusted for age, gender, and gender-treatment
Table 1 Demographic and disease-specific characteristics in the three treatment subgroups
No DMARDs, N = 79 bDMARD, N = 52 Methotrexate, N = 34 p value a/b/c
Demographic characteristics
Sex (M/F) 31/48 29/23 17/17 −/−/−
Age, (mean ± SD) 49.3 ± 12.0 48.0 ± 11.7 50.9 ± 11.3 −/−/−
Body mass index, (mean ± SD) 28.6 ± 6.2 29.0 ± 6.0 28.8 ± 6.4 −/−/−
Smokers, N (%) 24 (30) 12 (23) 7 (21) −/−/−
Menopause, N (%) 21 (27) 12 (23) 7 (21) −/−/−
Previous fracture, N (%)‡ 4 (5) 2 (4) 2 (6) −/−/−
Disease-specific characteristics
Duration of PSO (years), (mean ± SD) 18.1 ± 16.1 20.2 ± 11.1 20.3 ± 16.4 −/−/−
Duration of PsA (years), (mean ± SD) 2.9 ± 5.2 7.8 ± 7.4 4.6 ± 7.4 < 0.001/0.011/0.018
MDA, N (%) 28 (35) 25 (48) 22 (65) −/0.004/−
DAPSA
DAPSA score, (mean ± SD) 17.0 ± 11.4 12.3 ± 9.6 15.8 ± 17.8 0.009/−/−
Remission, N (%) 7 (9) 10 (19) 6 (18) −/−/−
Low activity, N (%) 29 (37) 25 (48) 13 (38) −/−/−
Moderate activity, N (%) 24 (30) 12 (23) 9 (27) −/−/−
High activity, N (%) 12 (15) 2 (4) 4 (12) 0.040/−/−
Nail involvement, N (%) 20 (25) 7 (14) 8 (24) −/−/−
Scalp involvement, N (%) 35 (44) 8 (15) 8 (24) 0.002/−/−
PASI (units), (mean ± SD) 4.0 ± 4.7 1.2 ± 2.7 2.1 ± 7.9 < 0.001/0.001/−
DLQI (units), (mean ± SD) 7.5 ± 6.5 3.2 ± 5.3 6.0 ± 5.3 0.043/−/−
HAQ (units), (mean ± SD) 0.6 ± 0.5 0.5 ± 0.5 0.7 ± 0.8 −/−/−
Diabetes mellitus, N (%) 2 (3) 3 (6) 2 (6) −/−/−
Hypertension, N (%) 19 (24) 14 (27) 5 (15) −/−/−
Autoantibody status
Positive low-titer ACPA, N (%)* 1 (1) 0 1 (3) −/−/−
Positive low-titer RF, N (%)** 3 (4) 0 1 (3) −/−/−
Anti-rheumatic and bone treatments
Vitamin D supplementation, N (%) 10 (13) 11 (21) 9 (27) −/−/−
Bisphosphonates, N (%) 0 1 (2) 0 −/−/−
Current glucocorticoids, N (%) 0 6 (12) 5 (15) 0.002/0.001/−
Former glucocorticoids intake, N (%) 4 (5) 13 (25) 5 (15) 0.001/−/−
Duration of glucocorticoids intake (years), (mean ± SD) 1.1 ± 1.0 2.8 ± 2.2 0.4 ± 0.2 −/−/0.034
Bonferroni-Holm adjustment: critical p values indicating significant results (italicize p values) for all investigated parameters were as follows: p1 = 0.0167,
p2 = 0.025, p3 = 0.05
ACPA anti-citrullinated protein antibody, bDMARDs biologic disease-modifying anti-rheumatic drugs, N number, PASI Psoriasis Area and Severity Index, PsA
psoriatic arthritis, PSO psoriasis, MDA minimal disease activity, DAPSA Disease Activity Index for Psoriatic Arthritis, DLQI Dermatology Life Quality Index, HAQ health
assessment questionnaire, RF rheumatoid factor, a no therapy vs. bDMARD, b no therapy vs. methotrexate, c bDMARD vs. methotrexate
*< 20 U/mL; **> 50 IE/mL
‡Fracture in adult life that occured spontaneously, or fractures caused by trauma that would not have led to a fracture in a healthy person
a no therapy vs. bDMARD
b no therapy vs. Methotrexate
c bDMARD vs. methotrexate
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interaction. As a sensitivity analysis, we re-ran the
models including MDA. All data manipulation and ana-
lyses were conducted using R (V3.5.1, R Foundation for
Statistical Computing, Vienna, Austria.).
Results
Characteristics of psoriatic arthritis patients
One hundred sixty-five PsA patients were included, 86
of them received DMARD treatment. Thirty-four PsA
patients received MTX, and 52 bDMARDs for at least 6
months. Within the bDMARD group, 31 patients had
TNF inhibitors (13 adalimumab, 6 infliximab, 9 etaner-
cept, 2 certolizumab, and 1 golimumab), 16 patients re-
ceived the IL-17A inhibitor secukinumab, and 5 patients
the IL12/23 inhibitor ustekinumab. The mean duration
of bDMARD treatment was 3.9 ± 3.3 years. Eleven pa-
tients in the bDMARD group had received previous
MTX, while no bDMARD patient per definition received
concurrent MTX. Seventy-nine PsA patients serving as
the control group received no DMARDs. Detailed infor-
mation on the demographic and disease-specific charac-
teristics of the patients is shown in Table 1. Briefly, age
and sex distribution, functional index, and comorbidities
were not different among the no-DMARD, MTX, and
bDMARD groups. The use of bone-active treatments
such as vitamin D and anti-resorptive drugs was also
balanced. A greater proportion of bDMARD-treated PsA
patients received glucocorticoids compared to the no-
DMARD group (p = 0.002). In addition, a larger propor-
tion of patients under bDMARD therapy had received
glucocorticoids in the past (p = 0.001) and hence had a
longer duration of glucocorticoid therapy.
bDMARD-treated PsA patients had also the longest
disease duration (7.6 ± 8.4 years; p < 0.001 compared to
no DMARDs) followed by the MTX group (4.6 ± 7.4)
and the no-DMARD group (2.9 ± 5.2). With respect to
disease control, more of the patients receiving
bDMARDs (48%) and MTX (65%) were in the MDA
state than those in the no-DMARD group (35%).
Better bone microstructure and functional properties in
PsA patients taking DMARDs
We first compared the no-DMARD control group with
PsA patients taking any DMARDs (MTX or bDMARDs)
Table 2 Comparison of bone structure and biomechanical properties in no-DMARD-, methotrexate-, and bDMARD-treated PsA
patients
No DMARDs (N = 79) Methotrexate (N = 34) bDMARDs (N = 52) p value
a/b
Finite element analysis
Stiffness (kN/mm), (mean ± SD) 45.2 ± 13.7 46.7 ± 14.2 52.1 ± 15.0b −/0.012
Failure load (N), (mean ± SD) 2154 ± 621 2242 ± 645 2473 ± 704b −/0.012
Bone parameters
Volumetric bone mineral density
Dtotal mg HA/cm3, (mean ± SD) 290 ± 54 299 ± 63 320 ± 44b −/0.001
Dtrab, mg HA/cm3, (mean ± SD) 156 ± 39 166 ± 40 174 ± 36b −/0.005
Dmeta, mg HA/cm3, (mean ± SD) 214 ± 38 222 ± 39 236 ± 35b −/0.001
Dinn, mg HA/cm3, (mean ± SD) 116 ± 41 127 ± 43 132 ± 40b −/0.026
Dcomp, mg HA/cm3, (mean ± SD) 817 ± 57 817 ± 72 831 ± 43 −/−
Meta/Inn, %, (mean ± SD) 1.9 ± 0.5 1.9 ± 0.8 2.0 ± 0.8 −/−
Bone microstructure
BV/TV, %, (mean ± SD) 0.13 ± 0.03 0.14 ± 0.03 0.15 ± 0.03b −/0.005
Tb.N, 1/mm, (mean ± SD) 1.99 ± 0.35 2.05 ± 0.36 2.12 ± 0.32b −/0.022
TbTh, mm, (mean ± SD) 0.065 ± 0.010 0.067 ± 0.011 0.069 ± 0.010b −/0.030
Tb.Sp, mm, (mean ± SD) 0.47 ± 0.18 0.44 ± 0.10 0.42 ± 0.11b −/0.010
Tb.1/N.SD, mm, (mean ± SD) 0.21 ± 0.16 0.19 ± 0.08 0.19 ± 0.13b −/0.017
Ct.Th, mm, (mean ± SD) 0.71 ± 0.16 0.73 ± 0.18 0.80 ± 0.15b −/0.001
Bone area
Cross-sectional area (mean ± SD) 321 ± 76 335 ± 88 325 ± 80 −/−
Bonferroni-Holm adjustment: critical p values indicating significant results (bold p values) for all investigated parameters were as follows: p1 = 0.0167,
p2 = 0.025, p3 = 0.05
bDMARDs biologic disease-modifying anti-rheumatic drugs, Dtotal total vBMD, Dtrab trabecular vBMD, Dcomp compact vBMD, Dmeta meta trabecular vBMD, Dinn
inner trabecular vBMD, meta/inn ratio of meta-to-inner density, BV/TV trabecular bone volume fraction, Tb.N number of trabeculae, Tb.Th trabecular thickness,
Tb.Sp trabecular separation, Tb.1/N.SD inhomogeneity of network, Ct.Th cortical thickness, a/b: a no DMARDs vs. methotrexate, b no DMARDs vs. bDMARD
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. DMARD patients had higher total vBMD (312 ± 53 vs.
290 ± 54, p = 0.004) and trabecular vBMD (171 ± 38 vs.
156 ± 39, p = 0.010) compared to no-DMARD controls.
In addition, they had better bone microstructure indi-
cated by higher number of trabeculae (2.09 ± 0.33 vs.
1.99 ± 0.35, p = 0.047), lower trabecular separation (0.43 ±
0.11 vs. 0.47 ± 0.18, p = 0.025), and higher cortical thick-
ness (0.77 ± 0.17 vs. 0.71 ± 0.16, p = 0.0012). Regarding
biomechanical properties, patients receiving DMARDs
had higher stiffness and failure load (stiffness, 50.0 ± 15.0
vs. 45.2 ± 13.7, p = 0.034; failure load, 2385 ± 687 vs.
2154 ± 621, p = 0.026).
Better bone microstructure and functional properties is
confined to PsA patients taking bDMARDs
To test whether the observed better bone status of
DMARD-treated PsA patients is based on MTX or
bDMARD treatment, we compared bone parameters be-
tween the no-DMARD control group and the MTX or
the bDMARD group, respectively. The results demon-
strated that MTX had no influence on bone microstruc-
ture and functional properties (Table 2). In contrast, and
despite their longer disease duration, the bDMARD
group exhibited significantly higher total and trabecular
vBMD (320 ± 44 vs. 290 ± 54, p = 0.001; 174 ± 36 vs.
Fig. 1 HR-pQCT and finite element analysis. (Left) Psoriatic arthritis (PsA) patient without disease-modifying anti-rheumatic drugs (DMARDs);
(right) PsA patient under biological DMARD treatment. Both patients had the same age and sex. a, b Axial view of three-dimensional
reconstruction of the cortical bone. c, d Axial view of the trabecular bone. e, f Axial view of finite element analysis-derived stress distribution (full
μFEA models). g, h Coronal view of finite element analysis-derived stress distribution. Colors in e–h depict von Mises stress (MPa) for the
described loading scenario
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156 ± 39, p = 0.005) as compared to the no-DMARD
group. In addition, higher cortical thickness (0.80 ± 0.15
vs. 0.71 ± 0.16, p = 0.001), with numerically higher num-
bers and thicker trabeculae (2.12 ± 0.32 vs. 1.99 ± 0.35,
p = 0.022; 0.069 ± 0.010 vs. 0.065 ± 0.010, p = 0.030 (the
adjusted significance was not met) were observed in the
bDMARD group. Furthermore, also the biomechanical
properties of bone (stiffness, 52.1 ± 15.0 vs. 45.2 ± 13.7,
p = 0.012; failure load, 2473 ± 704 vs. 2154 ± 621, p =
0.012) were better in the bDMARD group than in the
no-DMARD group (Table 2, Fig. 1).
Bone structure and function in PsA patients depend on
age, sex, bDMARD therapy, and disease activity state
To test the impact of bDMARD treatment on bone
structure and function, we set up three regression
models with total vBMD, stiffness, and failure load as
the respective outcome variable. We found that age and
bDMARD treatment had a significant impact on vBMD,
while age, sex, and bDMARD treatment influenced the
model stiffness and failure load (Table 3). Use of
bDMARD treatment, despite the longer disease duration
and higher proportion of corticosteroid use, was associ-
ated with better bone density and higher stiffness and
failure load estimates while no such association was ob-
served with the use of methotrexate in comparison to
no-DMARD use. When adding minimal disease activity
(MDA) to the regression models, results remained ro-
bust (Additional file 1: Table S1).
Discussion
The results of this study reveal that PsA patients receiv-
ing bDMARDs show better bone microstructure and
biomechanical properties as compared to PsA patients
receiving no DMARD treatment. In contrast, such differ-
ences are not found in PsA patients receiving MTX
treatment suggesting that the beneficial bone effect of
DMARD treatment in PsA is confined to the use of
bDMARDs. These data are remarkable since bDMARD-
treated PsA patients are a selectively more active and
more resistant patient population, including a higher
glucocorticoid use, which would reflect a higher burden
of disease on the bone. However, we found the bone
structure in bDMARD-treated PsA patients is not worse
but even better that in the control population compris-
ing patients with mild disease indicating a specific bene-
ficial effect of bDMARDs on the bone. Notably, this
effect was observed despite significantly longer disease
duration in the bDMARD group.
These observations may be explained by previous
functional data showing that the two central pro-
inflammatory mediators in PsA, IL-17 and TNF, trigger
an imbalance in bone homeostasis, increasing osteoclast-
medicated bone resorption and inhibiting osteoblast-
medicated bone formation [25–28]. This concept of
cytokine-mediated bone loss in PsA is in fact supported
by this study showing that PsA patients treated with ei-
ther IL-17 inhibitor or TNFa inhibitors show better
structural and functional bone data. We did not find sig-
nificant differences in bone structure and function be-
tween IL-17 inhibitor- and TNFa inhibitor-treated PsA
patients, suggesting a similar impact of the two main
bDMARD treatment strategies on systemic bone in PsA.
Methotrexate monotherapy did not impact bone struc-
ture or function in PsA patients. Values for bone mass,
microstructure, and function were consistently in the
range of no-DMARD controls. This finding is interesting
since the control of signs and symptoms of PsA was
similar in the MTX- and bDMARD-treated groups.
Hence, indirect effects such as better control of inflam-
mation by bDMARDs are less likely to attribute for these
differences. This notion is also supported by the fact that
the inclusion of minimal disease activity in the regres-
sion models did not affect the results. On the other
hand, methotrexate does not seem to share the positive
effects of cytokine blockade on the bone. Hence, metho-
trexate has shown to inhibit osteoblast differentiation
and bone formation [29], preventing that the anti-
inflammatory effects of MTX are accompanied by suffi-
cient rebalancing of the disturbed bone homeostasis.
Table 3 Regression models
Estimates CI p value
Total vBMD
Intercept 362.37 325.84–398.90 < 0.001
Age − 1.57 − 2.23 to − 0.91 < 0.001
Female 9.09 − 13.47–31.65 0.427
bDMARDs 43.52 18.18–68.86 0.001
Methotrexate 12.12 − 17.47–41.71 0.420
Stiffness
Intercept 68.65 60.90–76.40 < 0.001
Age − 0.28 − 0.42 to − 0.14 < 0.001
Female − 15.66 − 20.51 to − 10.82 < 0.001
bDMARDs 6.81 1.43–12.18 0.013
Methotrexate − 0.67 − 7.06–5.72 0.835
Failure load
Intercept 3227.06 2879.26–3574.86 < 0.001
Age − 12.77 − 19.06 to − 6.49 < 0.001
Female − 732.60 − 949.97 to − 515.22 < 0.001
bDMARDs 322.23 80.84–563.63 0.009
Methotrexate − 4.88 − 291.73–281.97 0.973
Reference for the change is the no treatment group. Models are adjusted for
age, gender, and treatment-gender interaction
vBMD volumetric bone mineral density, bDMARDs biologic disease-modifying
anti-rheumatic drugs, CI confidence interval
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A limitation of this study is the fact that it is cross-
sectional and not longitudinal. Thus, we cannot con-
clude that bDMARDs increase bone mass and/or im-
prove bone biomechanics in individual patients.
Nonetheless, considering the longer disease duration of
DMARD-treated than naïve PsA patients and the prefer-
ential use of bDMARDs in more severe PsA cases would
suggest more severe rather than milder bone disease in
bDMARD-treated patients. Since the exact opposite out-
come was observed, the data support a direct effect of
bDMARDs on bone structure and function in PsA. Fur-
thermore, patient groups were balanced for several factors
that could influence the bone including age and sex and
comorbidities like diabetes mellitus, which have recently
been shown to influence bone structure in PsA [30] as
well as bone-active therapies. As a next step, a longitu-
dinal study based on repeated HR-pQCT measurements
will be necessary to better understand the effects of indi-
vidual bDMARDs on bone homeostasis in PsA.
Conclusions
In summary, this study shows that the use of bDMARDs
is associated with better bone structure and function in
PsA patients. Given that PsA is associated with increased
fracture risk, fast and adequate neutralization of the key
pro-inflammatory and bone-destructive mediators seems
to be important to restore bone health and to limit frac-
ture risk in PsA patients.
Additional file
Additional file 1: Table S1. Regression models. (DOCX 18 kb)
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